
Primary tabs
Export 71 results:
Filters: Author is Marc Van den Bulcke
Contextual factors influencing the equitable implementation of precision medicine in routine cancer care in Belgium,
, European Journal of Public Health, Apr-03-2026, (2024)
Policy brief Belgian EBCP Mirror Group - Artificial Intelligence in cancer care,
, Archives of Public Health, Jan-08-2024, Volume 82, Issue S1, (2024)
Policy brief Belgian EBCP Mirror Group – cancer research in Belgium,
, Archives of Public Health, Jan-12-2024, Volume 82, Issue S1, (2024)
Unlocking the genomic landscape: Results of the Beyond 1 Million Genomes (B1MG) pilot in Belgium towards Genomic Data Infrastructure (GDI),
, Health Policy, Jan-05-2024, Volume 143, (2024)
Precision cancer medicine: What has translated into clinical use in Belgium?,
, Seminars in Cancer Biology, 2022, Volume 84, p.255 - 262, (2022)
PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.,
, ESMO Open, 2022 Aug, Volume 7, Issue 4, (2022)
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factorsBackgroundMethodsResultsConclusionDataSheet_1.docx,
, Frontiers in Immunology, Oct-12-2023, Volume 13, (2022)
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.,
, Front Immunol, 2022, Volume 13, (2022)
The Belgian practice and attitudes towards introducing genomics in clinical oncology,
, Belgian journal of medical oncology, 2021, Volume 15, Issue 4, p.177 - 185, (2021)
IPAAC Rapport WP4 : Cancer control policy interview survey,
, p.48, (2021)
Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes.,
, Clin Infect Dis, 2021 Dec 03, (2021)
Precision cancer medicine: What has translated into clinical use in Belgium?,
, Semin Cancer Biol, 2021 Jun 12, (2021)
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.,
, ESMO Open, 2021 Oct, Volume 6, Issue 5, (2021)
NGS for (Hemato-) Oncology in Belgium: Evaluation of Laboratory Performance and Feasibility of a National External Quality Assessment Program,
, Cancers, Jan-11-2020, Volume 12, Issue 11, (2020)
Towards a European health research and innovation cloud (HRIC),
, Genome Medicine, Jan-12-2020, Volume 12, Issue 1, (2020)
Algorithms for molecular testing in solid tumours,
, Belgian Journal of Medical Oncology (BJMO, nov 2019, Volume 13, Issue 7, Number 295, (2019)
Diagnostic testing in myeloid malignancies by next-generation sequencing: recommendations from the commission personalised medicine,
, Belgian Journal of Hematology, 2019, Volume 10, Issue 6, Number 249, (2019)
Molecular test algorithms for breast tumours,
, Belgian Journal of Medical Oncology, 2019, Volume 13, Issue 2, Number 45, (2019)
The genetic structure of the Belgian population,
, Human Genomics, Jan-12-2018, Volume 12, Issue 1, (2018)
Opportunities and challenges in oncology and molecular testing: the Belgian strategy,
, Belg J Med Oncol , 2018, Volume 12, Issue 2, Number 50, (2018)
Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting.,
, Semin Cancer Biol, 2018 10, Volume 52, Issue Pt 2, (2018)
Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato-oncology in Belgium.,
, Arch Public Health, 2018, Volume 76, (2018)
BelPHG-21: a pilot study on genetic variability in the Belgian population,
, European Public Health Conference , Stockholm, (2017)
CanCon European Guide on Quality Improvement in Comprehensive Cancer Control - Chapter 1: Introduction,
, CanCon, Number 18, (2017)